Decision Making, Shared, Prostate Cancer, Prostate-Specific Antigen
Conditions
Brief summary
In this project, the investigators aim to evaluate the most appropriate design and implementation strategy of a decision-aid to promote shared-decision making in prostate cancer screening.
Detailed description
Prostate cancer (PC) screening using Prostate Specific Antigen (PSA) has led to a reduction in advanced disease and disease-specific mortality. However, screening with PSA can also cause harm and is associated with false-positive results and overdiagnosis. Shared-decision making (SDM) has been defined as the key to successful patient-centered care. The promotion SDM when deciding on PSA screening will have proximal effects such as the development of collaborative deliberation between clinicians and patients, resulting in well-informed patients and in preference-based decisions. As long term effects, it will result in safer, cost-effective, patient-aligned healthcare, and its distant effects will include improvements in resource use, planning processes and improved health outcomes. The project includes a mixed-method approach. The investigators will perform a quantitative survey (cross-sectional design) to evaluate the population, patients' and clinicians' knowledge about the benefits and risks derived from the PSA determination and the available recommendations. The investigators will apply qualitative analysis through focus groups, to explore the challenges patients and clinicians face to deep in a prostate screening discussion and to assess the adequacy of different implementation strategies. The investigators will carry out a user-testing design based on mix-methods (questionnaire and semi-structured review) to evaluate the prototype of the initial decision-aid. Finally, the investigators will carry out a cluster randomised controlled trial, to assess the results derived from the application of the decision-aid, together with a process evaluation using a combination of both qualitative and quantitative methods to monitor the fidelity of the intervention, the clusters' and patients' response to the intervention as well as the mechanisms of adaptation and change at the intervention.
Interventions
OTHERMixed-method approach
Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
Sponsors
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Hospital de Sant Pau
Hospital Universitario San Juan de Alicante
Universidad Católica San Antonio de Murcia
Hospital General Universitario de Alicante
Universidad Miguel Hernandez de Elche
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. Patients: * Men \>40 years old * Men who have not had prostate cancer 2. General practitioners: * Primary care doctors working in the Valencian Community, Spain. 3. Urologists: * Urologists working in the Valencian Community, Spain.
Exclusion criteria
1. Patients: None 2. General practitioners: None 3. Urologists: None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients' and clinicians' knowledge on PSA test questionnaire developed by the investigators | December 2022 | Quantitative questionnaire to evaluate the target population and clinicians' knowledge about the PSA benefits/risks and the available recommendations. The investigators will develop an ad hoc questionnaire which will be validated through the Delphi Method. |
| Patients' and clinicians' opinions on PSA test | March 2023 | Focus groups to explore qualitatively the challenge patients and clinicians face when discussing prostate cancer screening and to assess their preferences about different designs and implementation strategies. |
| Number of patients who participated in a shared-decision making with their clinicians when receiving a PSA test | December 2023 | The investigators will assess the number of patients who participate in a shared- decision making with their clinicians when receiving a PSA test. To assess it, the investigators, through a randomized clinical trial, will apply a new decision-aid developed to a group of patients which will be compared with another group which will have normal care. |
Outcome results
None listed